| Literature DB >> 27697976 |
Peter E Clark1, Philippe E Spiess1, Neeraj Agarwal1, Rick Bangs1, Stephen A Boorjian1, Mark K Buyyounouski1, Jason A Efstathiou1, Thomas W Flaig1, Terence Friedlander1, Richard E Greenberg1, Khurshid A Guru1, Noah Hahn1, Harry W Herr1, Christopher Hoimes1, Brant A Inman1, A Karim Kader1, Adam S Kibel1, Timothy M Kuzel1, Subodh M Lele1, Joshua J Meeks1, Jeff Michalski1, Jeffrey S Montgomery1, Lance C Pagliaro1, Sumanta K Pal1, Anthony Patterson1, Daniel Petrylak1, Elizabeth R Plimack1, Kamal S Pohar1, Michael P Porter1, Wade J Sexton1, Arlene O Siefker-Radtke1, Guru Sonpavde1, Jonathan Tward1, Geoffrey Wile1, Mary A Dwyer1, Courtney Smith1.
Abstract
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction with the expert opinion of the panel. Recent updates include (1) refining the recommendation of intravesical bacillus Calmette-Guérin, (2) strengthening the recommendations for perioperative systemic chemotherapy, and (3) incorporating immunotherapy into second-line therapy for locally advanced or metastatic disease. These NCCN Guidelines Insights further discuss factors that affect integration of these recommendations into clinical practice.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27697976 PMCID： PMC5379654 DOI： 10.6004/jnccn.2016.0131
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908